These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 30374523)

  • 1. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
    Ergun Y; Bal O; Dogan M; Uncu D
    J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
    Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
    Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
    Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
    J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
    Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
    BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
    Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
    Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
    Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
    Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
    Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
    Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study.
    Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M
    JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
    Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
    Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
    Ozaslan E; Duran AO; Bozkurt O; Inanc M; Ucar M; Berk V; Karaca H; Elmali F; Ozkan M
    Asian Pac J Cancer Prev; 2015; 16(7):2833-8. PubMed ID: 25854370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
    Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
    Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
    Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
    J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
    Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
    Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
    Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
    BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
    BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
    Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
    Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.